Oncology Institute (NASDAQ:STLN – Free Report) had its price objective reduced by Lake Street Capital from $10.00 to $8.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the stock.
Several other research firms have also weighed in on STLN. Needham & Company LLC boosted their target price on shares of Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. B. Riley Financial restated a “buy” rating and set a $10.00 price target (down from $11.00) on shares of Oncology Institute in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a report on Tuesday, November 3rd. Finally, BTIG Research lifted their price target on shares of Oncology Institute from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Oncology Institute presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.25.
Get Our Latest Research Report on STLN
Oncology Institute Stock Performance
Oncology Institute (NASDAQ:STLN – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $169.77 million for the quarter. On average, analysts expect that Oncology Institute will post -0.21 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, Director Brad Hively sold 298,853 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $6.51, for a total value of $1,945,533.03. Following the sale, the director owned 411,976 shares in the company, valued at approximately $2,681,963.76. The trade was a 42.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett acquired 12,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average price of $6.54 per share, for a total transaction of $78,480.00. Following the acquisition, the insider directly owned 10,660,858 shares in the company, valued at approximately $69,722,011.32. This trade represents a 0.11% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 4.40% of the company’s stock.
Hedge Funds Weigh In On Oncology Institute
Institutional investors have recently bought and sold shares of the company. Legal & General Group Plc acquired a new position in shares of Oncology Institute in the second quarter valued at approximately $41,000. AMG National Trust Bank purchased a new stake in Oncology Institute during the 2nd quarter worth approximately $54,000. Engineers Gate Manager LP purchased a new stake in Oncology Institute during the 2nd quarter worth approximately $67,000. Royal Bank of Canada lifted its holdings in Oncology Institute by 335.9% during the 1st quarter. Royal Bank of Canada now owns 22,257 shares of the company’s stock worth $68,000 after buying an additional 17,151 shares in the last quarter. Finally, Fermata Advisors LLC acquired a new stake in Oncology Institute during the 2nd quarter worth approximately $70,000. 36.86% of the stock is owned by institutional investors and hedge funds.
About Oncology Institute
The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.
The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.
Further Reading
- Five stocks we like better than Oncology Institute
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.
